Magzter GOLDで無制限に
10,000以上の雑誌、新聞、プレミアム記事に無制限にアクセスできます。
試す 金 - 無料
Novo drug fails Alzheimer's tests
Mint New Delhi
|November 25, 2025
A pill version of Novo Nordisk A/S's Ozempic failed to slow the progression of Alzheimer’s disease in a pair of high-risk studies that aimed to open up a new use for blockbuster obesity drugs.
-
Patients who took the medicine didn’t see their disease progress more slowly based on a cognitive assessment, the Danish drugmaker said Monday.
このストーリーは、Mint New Delhi の November 25, 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Mint New Delhi からのその他のストーリー
Mint New Delhi
Softbank’s 40% fall from peak shows worry on OpenAI bet
Growing unease over frothy artificial intelligence (AI) valuations is weighing on shares of SoftBank Group Corp.
2 mins
November 27, 2025
Mint New Delhi
PepsiCo taps gourmet taste buds with Red Rock Deli’s India debut
Snack and cola maker PepsiCo is finally giving gourmet a chance with the launch of Red Rock Deli chips, priced ₹60 and ₹125 a pack, in a shift from its years-long focus on mass-market Lay's that starts as low as ₹5.
2 mins
November 27, 2025
Mint New Delhi
Fintechs turn fund magnets with cross-border licensing
Funders see growth prospects in central bank's payment aggregator-cross border licensing
3 mins
November 27, 2025
Mint New Delhi
'First-gen founders take bigger investment risks'
India’s markets are minting a new class of first-generation millionaires: entrepreneurs who’ve scaled ideas into Initial public offerings (IPOs) and unlocked unprecedented personal wealth.
2 mins
November 27, 2025
Mint New Delhi
Fundamentum readies four portfolio startups for IPOs
Nandan Nilekani-led venture capital firm Fundamentum is lining up at least four companies in its portfolio for a public listing over the next 12-24 months, co-founder and partner Ashish Kumar said.
2 mins
November 27, 2025
Mint New Delhi
Ukrainians resist pressure from Russia—and Trump
Battered by nearly 4 years of war, Ukrainians don’t want to make big concessions to Moscow
4 mins
November 27, 2025
Mint New Delhi
These firms will sell shovels during semaglutide gold rush
Weight-loss drug semaglutide, also used to treat type-2 diabetes, will face its next big turning point in early 2026, when patents held by Novo Nordisk expire in India.
2 mins
November 27, 2025
Mint New Delhi
IL&FS group repays ₹48,463 cr loan
Debt-ridden IL&FS group has repaid ₹48,463 crore to its creditors as of September 2025, out of the total ₹61,000 crore debt resolution target, as per the latest status report filed before insolvency appellate tribunal NCLAT.
1 min
November 27, 2025
Mint New Delhi
From playlists to pay-lists— streaming platforms go flexi
Audio streaming platforms reshape their business models to turn free listeners into paying subscribers, tiered pricing and micro-transactions have become key to their survival in a market where users are reluctant to pay for content.
2 mins
November 27, 2025
Mint New Delhi
AI trade splinters as Google challenges Nvidia’s dominance
Investors are sending two leaders of the AI trade in opposite directions.
3 mins
November 27, 2025
Listen
Translate
Change font size